Sigachi Industries Limited has announced that Trimax Biosciences, a Sigachi Group Company has received a communication from European Directorate for the Quality of Medicines & Health Care (EDQM) on its latest CEP Filing submission of “Propafenone Hydrochloride”. Achieving the Certificate of Suitability for this API will enable the company to export this product in Europe and other CEP accepting countries.

Commenting on this development, Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited stated: “The submission of our first CEP filing is a testament to Trimax Biosciences’ commitment to quality, compliance, and innovation in the API domain. This achievement not only strengthens our position in the pharmaceutical supply chain but also aligns with our vision of providing reliable and sustainable pharmaceutical solutions on a global scale.”